W ElMaraachli1, M Slater2, Z L Berrada3, S-Y G Lin3, A Catanzaro1, E Desmond3, C Rodrigues4, T C Victor5, V Crudu6, M T Gler7, T C Rodwell1. 1. Department of Medicine, University of California San Diego, San Diego, USA. 2. Department of Medicine, Stanford University School of Medicine, Stanford, USA. 3. California Department of Public Health, Richmond, California, USA. 4. Department of Microbiology, P D Hinduja Hospital Medical Research Centre, Veer Sarvarkar Marg, Mumbai, India. 5. Department of Biomedical Sciences, Stellenbosch University, Cape Town, South Africa. 6. Microbiology and Morphology Laboratory, Institute of Phthisiopneumology, Chisinau, Moldova. 7. Tropical Disease Foundation/Makati Medical Center, Makati City, The Philippines.
Abstract
SETTING: Rifampin (RMP) resistant Mycobacterium tuberculosis is usually assumed to be resistant to all rifamycins. Increasing evidence indicates, however, that some rpoB mutations, detectable by rapid molecular diagnostics, confer resistance to RMP but not to rifabutin (RBT), suggesting that RBT may be effective for the treatment of M. tuberculosis with these mutations. OBJECTIVE: To determine if specific rpoB mutations reliably predict differential phenotypic resistance to RMP and RBT. DESIGN: We selected 60 clinical M. tuberculosis isolates from a repository of multinational multidrug-resistant tuberculosis isolates and stratified them into two groups: 1) those with rpoB mutations suspected to confer differential resistance to RMP and RBT, and 2) those expected to be cross-resistant to RMP and RBT. These assumptions were tested by comparing the phenotypic susceptibilities of RMP/RBT with those predicted by mutations in the rpoB gene. RESULTS: Of 20 suspected RMP-resistant/RBT-susceptible isolates, 15 were RMP-resistant but RBT-susceptible, 3 were RMP- and RBT-susceptible, and 2 were cross-resistant to both RMP and RBT. In comparison, 40 of 40 suspected cross-resistant isolates were both RMP- and RBT-resistant. CONCLUSION: Our data support the association between specific rpoB mutations and differential resistance of M. tuberculosis to RMP and RBT. Clinical studies are required to investigate the efficacy of RBT in the treatment of M. tuberculosis harboring these mutations.
SETTING:Rifampin (RMP) resistant Mycobacterium tuberculosis is usually assumed to be resistant to all rifamycins. Increasing evidence indicates, however, that some rpoB mutations, detectable by rapid molecular diagnostics, confer resistance to RMP but not to rifabutin (RBT), suggesting that RBT may be effective for the treatment of M. tuberculosis with these mutations. OBJECTIVE: To determine if specific rpoB mutations reliably predict differential phenotypic resistance to RMP and RBT. DESIGN: We selected 60 clinical M. tuberculosis isolates from a repository of multinational multidrug-resistant tuberculosis isolates and stratified them into two groups: 1) those with rpoB mutations suspected to confer differential resistance to RMP and RBT, and 2) those expected to be cross-resistant to RMP and RBT. These assumptions were tested by comparing the phenotypic susceptibilities of RMP/RBT with those predicted by mutations in the rpoB gene. RESULTS: Of 20 suspected RMP-resistant/RBT-susceptible isolates, 15 were RMP-resistant but RBT-susceptible, 3 were RMP- and RBT-susceptible, and 2 were cross-resistant to both RMP and RBT. In comparison, 40 of 40 suspected cross-resistant isolates were both RMP- and RBT-resistant. CONCLUSION: Our data support the association between specific rpoB mutations and differential resistance of M. tuberculosis to RMP and RBT. Clinical studies are required to investigate the efficacy of RBT in the treatment of M. tuberculosis harboring these mutations.
Authors: S-Y Grace Lin; Timothy C Rodwell; Thomas C Victor; Errin C Rider; Lucy Pham; Antonino Catanzaro; Edward P Desmond Journal: J Clin Microbiol Date: 2013-11-27 Impact factor: 5.948
Authors: Timothy C Rodwell; Faramarz Valafar; James Douglas; Lishi Qian; Richard S Garfein; Ashu Chawla; Jessica Torres; Victoria Zadorozhny; Min Soo Kim; Matt Hoshide; Donald Catanzaro; Lynn Jackson; Grace Lin; Edward Desmond; Camilla Rodrigues; Kathy Eisenach; Thomas C Victor; Nazir Ismail; Valeru Crudu; Maria Tarcela Gler; Antonino Catanzaro Journal: J Clin Microbiol Date: 2013-12-18 Impact factor: 5.948
Authors: F B Jamieson; J L Guthrie; A Neemuchwala; O Lastovetska; R G Melano; C Mehaffy Journal: J Clin Microbiol Date: 2014-04-16 Impact factor: 5.948
Authors: T Schön; P Juréen; E Chryssanthou; C G Giske; G Kahlmeter; S Hoffner; K Angeby Journal: J Antimicrob Chemother Date: 2013-04-30 Impact factor: 5.790
Authors: Giuseppe Losurdo; Andrea Iannone; Floriana Giorgio; Mariabeatrice Principi; Alfredo Di Leo; Enzo Ierardi Journal: United European Gastroenterol J Date: 2015-12-15 Impact factor: 4.623
Authors: Eleanor S Click; Ekaterina V Kurbatova; Heather Alexander; Tracy L Dalton; Michael P Chen; James E Posey; Julia Ershova; J Peter Cegielski Journal: J Infect Dis Date: 2020-06-11 Impact factor: 5.226
Authors: Michael G Whitfield; Robin M Warren; Vanessa Mathys; Lesley Scott; Elise De Vos; Wendy Stevens; Elizabeth M Streicher; Guido Groenen; Frederick A Sirgel; Annelies Van Rie Journal: J Antimicrob Chemother Date: 2018-10-01 Impact factor: 5.790
Authors: Ivy Rukasha; Halima M Said; Shaheed V Omar; Hendrik Koornhof; Andries W Dreyer; Alfred Musekiwa; Harry Moultrie; Anwar A Hoosen; Gilla Kaplan; Dorothy Fallows; Nazir Ismail Journal: Front Microbiol Date: 2016-12-05 Impact factor: 5.640
Authors: Jae Ho Choi; Young Joo Yang; Chang Seok Bang; Jae Jun Lee; Gwang Ho Baik Journal: Gastroenterol Res Pract Date: 2018-05-02 Impact factor: 2.260
Authors: Muhammad Miftahussurur; Modesto Cruz; Dalla Doohan; Phawinee Subsomwong; José A Jiménez Abreu; Celso Hosking; Langgeng Agung Waskito; Yoshio Yamaoka Journal: PLoS One Date: 2019-03-27 Impact factor: 3.240
Authors: F A Gopie; E Commiesie; S Baldi; M Kamst; D Kaur; W C M de Lange; P S Pinas; D Stijnberg; M Wongsokarijo; C W R Zijlmans; R de Zwaan; D van Soolingen; S G S Vreden; G de Vries Journal: J Clin Tuberc Other Mycobact Dis Date: 2021-01-29